1Clinical Trial Center, Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea
2Department of Diagnostics, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea
3Research Center of Traditional Korean Medicine, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea
4Department of Il-won Integrative Medicine, Wonkwang University Korean Medicine Hospital, Iksan, Republic of Korea
5Center for Brain and Nervous System Disorders, Daejeon Korean Medicine Hospital of Daejeon University, Daeejon, Republic of Korea
©2025 Jaseng Medical Foundation
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Acknowledgments
This study is submitted as a revision and supplementation of the doctoral dissertation of the first author, Wangjung Hur.
Author Contributions
Conceptualization: HY. Methodology: WH, JL, and HY. Formal investigation: WH, JL, and HJ. Data analysis: MP and SP. Writing original draft: WH and JL. Writing - review and editing: WH, JL, HJ, MP, SP, and HY.
Conflicts of Interest
The authors declare that they have no conflict of interest. The funders had no role in the design of the study, data collection, analysis and interpretation, manuscript writing, or decision to publish the results.
Funding
This work was supported by 2 National Research Foundation of Korea grants funded by the Korean government (no.: RS-2019-NR042116 and RS-2022-NR070207).
Ethical Statement
This study was approved by the Institutional Review Board of Daejeon University (no.: 1040647-2102-HR-002-03). The protocol was registered with the Clinical Research Information Service at the Korea Disease Control and Prevention Agency (CRIS; KCT0007483).
Continuous data are presented as mean ± SD, whilst categorical data are presented as frequency and percentage.
The dopamine precursor category includes medications such as Levodopa, while the dopamine agonist category includes examples like Pramipexole and Ropinirole; the MAO-B inhibitor category includes Rasagiline; and the COMT inhibitor category includes Opicapone.
COMT = catechol-o-methyltransferase; MAO-B = monoamine oxidase-B; PD = Parkinson’s disease.
Variables (n = 9) | 0 week (mean ± SD) | 10 weeks (mean ± SD) | 0–10 weeks (mean difference) | p |
---|---|---|---|---|
NMSS1 | 4.4 ± 2.6 | 3.7 ± 2.9 | 0.7 ± −0.3 | 0.34 |
NMSS2 | 19.1 ± 11.4 | 15.3 ± 10.3 | 3.8 ± 1.1 | 0.09 |
NMSS3 | 17.1 ± 13.9 | 10.2 ± 5.7 | 6.9 ± 8.2 | 0.14 |
NMSS4 | 0.2 ± 0.6 | 0 ± 0 | 0.2 ± 0.6 | 0.32 |
NMSS5 | 6.1 ± 3.1 | 5.2 ± 4.7 | 0.9 ± −1.6 | 0.68 |
NMSS6 | 6.1 ± 5.2 | 4.9 ± 4.6 | 1.2 ± 0.6 | 0.15 |
NMSS7 | 9.4 ± 7.1 | 10 ± 11.5 | −0.6 ± −4.4 | 0.81 |
NMSS8 | 3.4 ± 3.3 | 1.4 ± 2.0 | 2 ± 1.3 | 0.02* |
NMSS9 | 13.3 ± 7.8 | 9 ± 6.5 | 4.3 ± 1.3 | 0.11 |
NMSS total | 79.3 ± 30.9 | 59.8 ± 26.1 | 19.5 ± 4.8 | 0.01* |
PDQ-39 | 42.1 ± 16.8 | 40.1 ± 8.5 | 2 ± 8.3 | 0.722 |
EQ-5D | 0.43 ± 0.24 | 0.44 ± 0.22 | −0.11 ± 0.02 | 0.86 |
EQ-VAS | 69.33 ± 11.30 | 69.44 ± 10.74 | −0.11 ± 0.56 | 0.89 |
UPDRS-I | 2.6 ± 2.1 | 1.0 ± 1.6 | 1.6 ± 0.6 | 0.03* |
UPDRS-II | 9.9 ± 5.1 | 8.7 ± 3.5 | 1.2 ± 1.6 | 0.22 |
UPDRS-III | 16 ± 7.5 | 20.3 ± 8.9 | −4.3 ± −1.4 | 0.02* |
UPDRS-IV | 5.1 ± 3.4 | 5.3 ± 4.0 | −0.2 ± −0.6 | 0.61 |
Hoehn and Yahr stage | 1.4 ± 0.4 | 1.9 ± 0.6 | −0.5 ± −0.2 | 0.12 |
Schwab & England ADL | 84.4 ± 10.7 | 88.9 ± 7.4 | 4.5 ± 3.3 | 0.01* |
* Statistically significant (p < 0.05).
The variables representing outcomes were analyzed using the Wilcoxon signed-rank test, a nonparametric test used to compare paired data before and after an intervention when the data are not normally distributed. A two-tailed test was performed, and the significance level was set at 0.05.
Data in the “mean difference” column were presented with consistent directional interpretation across all assessment measures, where positive signs represent symptom improvement and negative signs denote symptom deterioration.
ADL = activities of daily living; EQ-5D = EuroQol 5 dimensions 5 levels; EQ-VAS = EuroQol visual analog scale; H-Y stage = Hoehn and Yahr stage; NMSS = non-motor symptoms scale for Parkinson’s disease; PDQ-39 = 39-item Parkinson’s disease questionnaire; UPDRS = unified Parkinson’s disease rating scale.
Screening (wk 0) | Visit 1 (wk 1) | Visit 2–9 (wk 2–9) | Visit 10 (wk 10) | |
---|---|---|---|---|
Informed consent | X | |||
Demographics and medical history | X | |||
Cognitive assessment (MMSE) | X | |||
Parkinson related outcome: | ||||
NMSS | X | X | ||
PDQ-39 | X | X | ||
EQ-5D | X | X | ||
UPDRS | X | X | ||
Hoehn and Yahr stage | X | X | ||
Schwab & England ADL | X | X | ||
Art program | X |
Variables | Mean (± SD) or frequency (ratio) |
---|---|
Sex | |
Female | 6 (66.7) |
Male | 3 (33.3) |
Age (y) | 58.6 ± 4.57 |
Duration of Parkinson’s disease (y) | 5.1 ± 2.4 |
Hoehn and Yahr scale | 1.4 ± 0.4 |
Medications taken for PD: | |
Dopamine precursor | 4 (44.4) |
Dopamine agonist | 4 (44.4) |
MAO-B inhibitor | 1 (11.1) |
COMT inhibitor | 1 (11.1) |
Concomitant disease: | |
Hypertension | 1 (11.1) |
Diabetes mellitus | 0 (0) |
Hyperlipidemia | 2 (22.2) |
Stroke | 0 (0) |
Heart disease | 0 (0) |
Previous experience in art activities | 8 (88.9) |
Duration of the past art experience (y) | 0.2 ± 0.4 |
Variables (n = 9) | 0 week (mean ± SD) | 10 weeks (mean ± SD) | 0–10 weeks (mean difference) | p |
---|---|---|---|---|
NMSS1 | 4.4 ± 2.6 | 3.7 ± 2.9 | 0.7 ± −0.3 | 0.34 |
NMSS2 | 19.1 ± 11.4 | 15.3 ± 10.3 | 3.8 ± 1.1 | 0.09 |
NMSS3 | 17.1 ± 13.9 | 10.2 ± 5.7 | 6.9 ± 8.2 | 0.14 |
NMSS4 | 0.2 ± 0.6 | 0 ± 0 | 0.2 ± 0.6 | 0.32 |
NMSS5 | 6.1 ± 3.1 | 5.2 ± 4.7 | 0.9 ± −1.6 | 0.68 |
NMSS6 | 6.1 ± 5.2 | 4.9 ± 4.6 | 1.2 ± 0.6 | 0.15 |
NMSS7 | 9.4 ± 7.1 | 10 ± 11.5 | −0.6 ± −4.4 | 0.81 |
NMSS8 | 3.4 ± 3.3 | 1.4 ± 2.0 | 2 ± 1.3 | 0.02 |
NMSS9 | 13.3 ± 7.8 | 9 ± 6.5 | 4.3 ± 1.3 | 0.11 |
NMSS total | 79.3 ± 30.9 | 59.8 ± 26.1 | 19.5 ± 4.8 | 0.01 |
PDQ-39 | 42.1 ± 16.8 | 40.1 ± 8.5 | 2 ± 8.3 | 0.722 |
EQ-5D | 0.43 ± 0.24 | 0.44 ± 0.22 | −0.11 ± 0.02 | 0.86 |
EQ-VAS | 69.33 ± 11.30 | 69.44 ± 10.74 | −0.11 ± 0.56 | 0.89 |
UPDRS-I | 2.6 ± 2.1 | 1.0 ± 1.6 | 1.6 ± 0.6 | 0.03 |
UPDRS-II | 9.9 ± 5.1 | 8.7 ± 3.5 | 1.2 ± 1.6 | 0.22 |
UPDRS-III | 16 ± 7.5 | 20.3 ± 8.9 | −4.3 ± −1.4 | 0.02 |
UPDRS-IV | 5.1 ± 3.4 | 5.3 ± 4.0 | −0.2 ± −0.6 | 0.61 |
Hoehn and Yahr stage | 1.4 ± 0.4 | 1.9 ± 0.6 | −0.5 ± −0.2 | 0.12 |
Schwab & England ADL | 84.4 ± 10.7 | 88.9 ± 7.4 | 4.5 ± 3.3 | 0.01 |
ADL = activities of daily living; EQ-5D = EuroQol 5 dimensions 5 levels; MMSE = mini-mental state examination; NMSS = non-motor symptoms scale for Parkinson’s disease; PDQ-39 = 39-item Parkinson’s disease questionnaire; UPDRS = unified Parkinson’s disease rating scale.
Continuous data are presented as mean ± SD, whilst categorical data are presented as frequency and percentage. The dopamine precursor category includes medications such as Levodopa, while the dopamine agonist category includes examples like Pramipexole and Ropinirole; the MAO-B inhibitor category includes Rasagiline; and the COMT inhibitor category includes Opicapone. COMT = catechol-o-methyltransferase; MAO-B = monoamine oxidase-B; PD = Parkinson’s disease.
Statistically significant ( The variables representing outcomes were analyzed using the Wilcoxon signed-rank test, a nonparametric test used to compare paired data before and after an intervention when the data are not normally distributed. A two-tailed test was performed, and the significance level was set at 0.05. Data in the “mean difference” column were presented with consistent directional interpretation across all assessment measures, where positive signs represent symptom improvement and negative signs denote symptom deterioration. ADL = activities of daily living; EQ-5D = EuroQol 5 dimensions 5 levels; EQ-VAS = EuroQol visual analog scale; H-Y stage = Hoehn and Yahr stage; NMSS = non-motor symptoms scale for Parkinson’s disease; PDQ-39 = 39-item Parkinson’s disease questionnaire; UPDRS = unified Parkinson’s disease rating scale.